Envudeucitinib has shown sustained efficacy in treating moderate-to-severe psoriasis. The treatment has demonstrated both efficacy and safety in clinical trials, with some reports indicating significant improvements in symptoms such as itch and skin clearance. The results of phase 3 trials, including ONWARD1 and ONWARD2, have been reported, suggesting envudeucitinib may be a notable development in the psoriasis therapy landscape.